Refanalin

Unassigned

New Medicines

Renal transplant - prevention of delayed graft function

Information

New molecular entity
Not Known
Angion Biomedica

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Hepatocyte growth factor stimulant
DGF is a common cause of both short-term and long-term poor outcomes after kidney transplantation, and is responsible for significantly increasing costs. Estimated incidence of DGF after deceased-donor transplant varies widely, with expert estimates for England ranging from 35 to 883; about 30% of the transplant population may be at higher risk of DGF [6].
Renal transplant - prevention of delayed graft function
Intravenous

Evidence based evaluations